{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/human-genetic-resources-approvals-and-data-export-controls”
},
“@id”: “https://www.clinicalstudies.in/human-genetic-resources-approvals-and-data-export-controls”,
“headline”: “SOP for Human Genetic Resources Approvals and Data Export Controls”,
“name”: “SOP for Human Genetic Resources Approvals and Data Export Controls”,
“description”: “Comprehensive SOP covering submission, approval, and compliance processes for Human Genetic Resources (HGR) in China, including restrictions on data export and biological sample transfer under NMPA oversight.”,
“keywords”: “Human Genetic Resources SOP, HGR approval China, data export control SOP, SOP for HGR submissions, NMPA HGR governance, SOP for genetic material export, SOP for clinical trial HGR approval, HGR licensing SOP China, SOP for biological sample transfer China, NMPA human genetic resources approval, SOP for investigator obligations HGR, SOP for sponsor responsibilities HGR, ethics requirements HGR China, SOP for HGR governance compliance, SOP for cross-border sample transfer, HGR inspection readiness SOP, SOP for HGR application China, SOP for data export restrictions China, HGR sample storage SOP, HGR reporting SOP China, SOP for HGR compliance China, NMPA HGR oversight SOP, SOP for institutional HGR approvals, SOP for trial sponsor data export, SOP for HGR lifecycle events”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

Human Genetic Resources Approvals and Data Export Controls SOP

Purpose

This SOP establishes the procedures for securing approvals for the collection, use, storage, and export of Human Genetic Resources (HGR) in clinical trials conducted in China. It defines sponsor, investigator, and institutional responsibilities to ensure compliance with Chinese HGR regulations under the National Medical Products Administration (NMPA) and the Ministry of Science and Technology (MOST).

Scope

This SOP applies to all clinical trials in China involving human biological samples or genetic data. It includes requirements for HGR licensing, ethics approvals, collaboration with foreign entities, restrictions on cross-border data and sample transfer, and record-keeping obligations. It covers sponsor-level submissions, investigator responsibilities, and site-level documentation.

Responsibilities

• Sponsor: Ensures HGR application submissions, approvals, and compliance with MOST regulations before trial initiation.
• Principal Investigator (PI): Collects and stores HGR samples at the site, ensures no unapproved transfers occur, and maintains accurate logs.
• Regulatory Affairs (RA): Manages submission of HGR applications and amendments to MOST and NMPA.
• Clinical Project Manager (CPM): Coordinates timelines, tracks HGR approvals, and ensures sites have valid certificates.
• Quality Assurance (QA): Audits HGR compliance at sponsor and site levels and ensures readiness for inspection.

Accountability

The Sponsor is accountable for securing and maintaining valid HGR approvals and ensuring compliance with Chinese regulations. The PI is accountable for maintaining site-level governance of HGR use and preventing unauthorized data or sample transfers.

Procedure

1. Identification of HGR Requirements

1. Determine whether the trial involves collection, storage, or export of HGR samples or data.
2. Document requirements in HGR Assessment Form (Annexure-1).

2. HGR Application Submission

1. Prepare HGR Application Dossier including protocol, consent forms, investigator CVs, sample management plan, and data export justification (if applicable).
2. Submit application to MOST before trial initiation.
3. Record submission details in HGR Submission Log.

3. Ethics Committee Coordination

1. Submit HGR-related documents to EC along with protocol and ICFs.
2. Ensure subject consent forms include clauses on HGR use and export restrictions.

4. Restrictions on Export

1. No cross-border transfer of HGR data or samples without prior MOST approval.
2. Maintain HGR Export Approval Log for each export event.
3. Ensure electronic data storage is localized in China unless export is specifically approved.

5. Amendments

1. Submit amendments to HGR approvals if study design, sites, or sample management plans change.

6. Documentation and Archiving

1. Maintain HGR Submission Log, Export Approval Log, and EC approval letters in TMF.
2. Archive HGR-related documents for at least 15 years or per Chinese law.

Abbreviations

• HGR: Human Genetic Resources
• NMPA: National Medical Products Administration
• MOST: Ministry of Science and Technology
• CTA: Clinical Trial Application
• PI: Principal Investigator
• EC: Ethics Committee
• RA: Regulatory Affairs
• QA: Quality Assurance
• TMF: Trial Master File

Documents

1. HGR Assessment Form (Annexure-1)
2. HGR Submission Log (Annexure-2)
3. HGR Export Approval Log (Annexure-3)

References

• National Medical Products Administration (NMPA)
• Ministry of Science and Technology (MOST)
• ICH E6(R2) Good Clinical Practice
• ICH Efficacy Guidelines

Version: 1.0

Approval

Annexures

Annexure-1: HGR Assessment Form

Annexure-2: HGR Submission Log

Annexure-3: HGR Export Approval Log

Revision History

For more SOPs visit: Pharma SOP.